BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 28474339)

  • 1. Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study.
    Ellin F; Jerkeman M; Törnqvist J; Brudin L; Relander T
    Hematol Oncol; 2018 Feb; 36(1):159-165. PubMed ID: 28474339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry.
    Ellin F; Landström J; Jerkeman M; Relander T
    Blood; 2014 Sep; 124(10):1570-7. PubMed ID: 25006130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry.
    Pedersen MB; Hamilton-Dutoit SJ; Bendix K; Møller MB; Nørgaard P; Johansen P; Ralfkiaer E; Brown Pde N; Hansen PB; Jensen BA; Madsen J; Schöllkopf C; d'Amore F
    Hematol Oncol; 2015 Dec; 33(4):120-8. PubMed ID: 25052551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of clinical outcome after autologous stem cell transplantation between patients with peripheral T-cell lymphomas and diffuse large B-cell lymphoma.
    Sohn BS; Park I; Kim EK; Yoon DH; Lee SS; Kang BW; Jang G; Choi YH; Kim C; Lee DH; Kim S; Huh J; Suh C
    Bone Marrow Transplant; 2009 Sep; 44(5):287-93. PubMed ID: 19234508
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study.
    Wästerlid T; Mohammadi M; Smedby KE; Glimelius I; Jerkeman M; Bottai M; Eloranta S
    J Intern Med; 2019 Apr; 285(4):455-468. PubMed ID: 30368947
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Allogeneic transplantation following a reduced-intensity conditioning regimen in relapsed/refractory peripheral T-cell lymphomas: long-term remissions and response to donor lymphocyte infusions support the role of a graft-versus-lymphoma effect.
    Dodero A; Spina F; Narni F; Patriarca F; Cavattoni I; Benedetti F; Ciceri F; Baronciani D; Scimè R; Pogliani E; Rambaldi A; Bonifazi F; Dalto S; Bruno B; Corradini P
    Leukemia; 2012 Mar; 26(3):520-6. PubMed ID: 21904377
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of high-dose therapy in peripheral T-cell lymphomas.
    Reimer P; Rüdiger T; Wilhelm M
    Clin Lymphoma Myeloma; 2006 Mar; 6(5):373-9. PubMed ID: 16640812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of comorbidity in older patients with peripheral T-cell lymphoma: an international retrospective analysis of 891 patients.
    Mead M; Cederleuf H; Björklund M; Wang X; Relander T; Jerkeman M; Gaut D; Larson S; Ellin F
    Blood Adv; 2022 Apr; 6(7):2120-2128. PubMed ID: 34570186
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01.
    d'Amore F; Relander T; Lauritzsen GF; Jantunen E; Hagberg H; Anderson H; Holte H; Österborg A; Merup M; Brown P; Kuittinen O; Erlanson M; Østenstad B; Fagerli UM; Gadeberg OV; Sundström C; Delabie J; Ralfkiaer E; Vornanen M; Toldbod HE
    J Clin Oncol; 2012 Sep; 30(25):3093-9. PubMed ID: 22851556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas.
    Gritti G; Boschini C; Rossi A; Delaini F; Grassi A; Algarotti A; Micò C; Trezzi R; Gianatti A; Barbui AM; Rambaldi A
    PLoS One; 2015; 10(3):e0121822. PubMed ID: 25815886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral T cell lymphomas in elderly patients: a retrospective analysis from the Hematology Association of South East Korea (HASEK).
    Jo JC; Choi Y; Shin HJ; Yhim SN; Lee HS; Lee WS; Lee JH; Kim H; Oh SY
    Ann Hematol; 2016 Mar; 95(4):619-24. PubMed ID: 26779714
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors.
    Mak V; Hamm J; Chhanabhai M; Shenkier T; Klasa R; Sehn LH; Villa D; Gascoyne RD; Connors JM; Savage KJ
    J Clin Oncol; 2013 Jun; 31(16):1970-6. PubMed ID: 23610113
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Autologous stem cell transplantation as frontline strategy for peripheral T-cell lymphoma: A single-centre experience.
    Han X; Zhang W; Zhou D; Ruan J; Duan M; Zhu T; Li J; Cai H; Cao X; Ouyang M
    J Int Med Res; 2017 Feb; 45(1):290-302. PubMed ID: 28222648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcomes of peripheral blood stem cell transplantation for 38 patients with peripheral T-cell lymphoma.
    Bo J; Zhao Y; Zhang S; Hua W; Wang S; Gao C; Wang Q; Li H; Yu L
    J Cancer Res Ther; 2016; 12(3):1189-1197. PubMed ID: 28054534
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose therapy with autologous stem cell transplantation in patients with peripheral T cell lymphomas.
    Blystad AK; Enblad G; Kvaløy S; Berglund A; Delabie J; Holte H; Carlson K; Kvalheim G; Bengtsson M; Hagberg H
    Bone Marrow Transplant; 2001 Apr; 27(7):711-6. PubMed ID: 11360110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose chemotherapy and autologous stem cell transplantation in patients with peripheral T-cell lymphoma not achieving complete response after induction chemotherapy. The GEL-TAMO experience.
    Rodriguez J; Caballero MD; Gutierrez A; Gandarillas M; Sierra J; Lopez-Guillermo A; Sureda A; Zuazu J; Marin J; Arranz R; Carreras E; Leon A; De Sevilla AF; San Miguel JF; Conde E;
    Haematologica; 2003 Dec; 88(12):1372-7. PubMed ID: 14687990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
    Shustov A
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.
    Maurer MJ; Ellin F; Srour L; Jerkeman M; Bennani NN; Connors JM; Slack GW; Smedby KE; Ansell SM; Link BK; Cerhan JR; Relander T; Savage KJ; Feldman AL
    J Clin Oncol; 2017 Dec; 35(36):4019-4026. PubMed ID: 29072976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum IgA level, monocyte count, and international prognostic index are independently associated with overall survival in patients with HTLV-I-negative nodal peripheral T cell lymphoma.
    Kato A; Imai Y; Aoki K; Tabata S; Matsushita A; Hashimoto H; Takahashi T; Ishikawa T
    Ann Hematol; 2014 Jul; 93(7):1185-91. PubMed ID: 24526138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of high-dose therapy and stem cell rescue in the management of T-cell malignant lymphomas: a BSBMT and ABMTRR study.
    Feyler S; Prince HM; Pearce R; Towlson K; Nivison-Smith I; Schey S; Gibson J; Patton N; Bradstock K; Marks DI; Cook G
    Bone Marrow Transplant; 2007 Sep; 40(5):443-50. PubMed ID: 17589529
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.